Tower Research Capital (TRC)’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-9,938
| Closed | -$40K | – | 4440 |
|
|
2019
Q4 | $40K | Buy |
+9,938
| New | +$46.7K | ﹤0.01% | 1480 |
|
|
2019
Q3 | – | Sell |
-187
| Closed | -$1K | – | 4799 |
|
|
2019
Q2 | $1K | Sell |
187
-1,802
| -91% | -$9.58K | ﹤0.01% | 3567 |
|
|
2019
Q1 | $12K | Buy |
+1,989
| New | +$20.5K | ﹤0.01% | 2613 |
|
|
2018
Q3 | – | Sell |
-5,700
| Closed | -$146K | – | 4501 |
|
|
2018
Q2 | $146K | Buy |
5,700
+704
| +14% | +$16.4K | 0.01% | 1211 |
|
|
2018
Q1 | $101K | Buy |
4,996
+4,791
| +2,337% | +$112K | 0.01% | 1254 |
|
|
2017
Q4 | $4K | Sell |
205
-5,505
| -96% | -$108K | ﹤0.01% | 3036 |
|
|
2017
Q3 | $118K | Buy |
+5,710
| New | +$96.5K | 0.01% | 1199 |
|
|
2017
Q2 | – | Sell |
-100
| Closed | -$2K | – | 3802 |
|
|
2017
Q1 | $2K | Sell |
100
-5,679
| -98% | -$81.9K | ﹤0.01% | 2719 |
|
|
2016
Q4 | $72K | Sell |
5,779
-1,663
| -22% | -$31K | 0.01% | 1172 |
|
|
2016
Q3 | $208K | Buy |
7,442
+3,241
| +77% | +$109K | 0.02% | 461 |
|
|
2016
Q2 | $147K | Buy |
4,201
+4,168
| +12,630% | +$131K | 0.01% | 869 |
|
|
2016
Q1 | $1K | Sell |
33
-758
| -96% | -$22.3K | ﹤0.01% | 3897 |
|
|
2015
Q4 | $27K | Buy |
791
+552
| +231% | +$17.2K | ﹤0.01% | 999 |
|
|
2015
Q3 | $7K | Buy |
+239
| New | +$10.2K | ﹤0.01% | 2600 |
|
|
2015
Q2 | – | Sell |
-5,444
| Closed | -$188K | – | 5317 |
|
|
2015
Q1 | $188K | Buy |
5,444
+5,244
| +2,622% | +$143K | 0.02% | 449 |
|
|
2014
Q4 | $5K | Buy |
+200
| New | +$4.85K | ﹤0.01% | 2777 |
|
Other funds holding DPLO
Tower Research Capital (TRC)'s DPLO Position: Q1 2020 in Review
Tower Research Capital (TRC) sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2020, closing a stake of 9,938 shares — an estimated $40K sold.
Tower Research Capital (TRC) first reported a position in DPLO in Q4 2014 and held it in 16 quarters. The position peaked at $208K in Q3 2016. 1 fund tracked by Wall St. Rank holds DPLO as of Q1 2020.
- Tower Research Capital (TRC) reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 9,938 DIPLOMAT PHARMACY, INC. shares in Q1 2020, an estimated $40K.
- Tower Research Capital (TRC) first reported a position in DIPLOMAT PHARMACY, INC. in Q4 2014 and held it in 16 quarters.
- Tower Research Capital (TRC)'s DIPLOMAT PHARMACY, INC. position peaked at $208K in Q3 2016.
- 1 fund tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2020, filed 15 May 2020.